Events

Dr. Jonathan Bramson to be presenting at 3:20 p.m. CT on June 1.

At the IOBDLI Forum, Triumvira Scientific Founder and Acting Chief Scientific Officer, Dr. Jonathan Bramson, will provide an overview of the company’s T Cell-Antigen Coupler (TAC) technology, as well as updates on Triumvira’s lead drug, CD19-TAC01, which is targeted to enter clinical development in H1 2019 for the treatment of patients with CD19 positive B-cell malignancies. Dr. Bramson will be presenting at 3:20 p.m. CT on June 1.

Learn more and register here